Technical Analysis for CMPS - COMPASS Pathways Plc
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Down | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 50 DMA Resistance | Bearish | 0.59% | |
| 20 DMA Support | Bullish | 0.59% | |
| 200 DMA Support | Bullish | 0.59% | |
| Bollinger Band Squeeze | Range Contraction | 0.59% | |
| Wide Range Bar | Range Expansion | 0.59% | |
| Earnings Movers | Other | 0.59% | |
| BB Squeeze + Upper Band Touch | Range Contraction | 0.59% | |
| Outside Day | Range Expansion | 0.59% | |
| Upper Bollinger Band Touch | Strength | 0.59% | |
| 20 DMA Support | Bullish | 0.12% |
| Alert | Time |
|---|---|
| Up 2% | 14 minutes ago |
| 20 DMA Support | 25 minutes ago |
| 10 DMA Support | 25 minutes ago |
| 200 DMA Support | 25 minutes ago |
| Up 1% | 25 minutes ago |
Free Daily (Stock) Chart Reading
- Earnings date: 05/08/2024
COMPASS Pathways Plc Description
COMPASS Pathways plc is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. Our focus is on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. We are pioneering the development of a new model of psilocybin therapy, in which our proprietary formulation of synthetic psilocybin, COMP360, is administered in conjunction with psychological support. COMP360 has been designated a Breakthrough Therapy by the US Food and Drug Administration (FDA), for treatment-resistant depression (TRD), and we are currently conducting a phase IIb clinical trial of psilocybin therapy for TRD, in 20 sites across Europe and North America. We are headquartered in London, UK, with offices in New York, USA. Our vision is a world of mental wellbeing.
Classification
Sector: Healthcare
Industry: Medical Care Facilities
Keywords: Health Sciences Drug Discovery FDA Psychoactive Drugs Mental Health Entheogens Depression Major Depressive Disorder Breakthrough Therapy MP3 Treatment Resistant Depression Psilocybin
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 12.75 |
| 52 Week Low | 5.01 |
| Average Volume | 660,331 |
| 200-Day Moving Average | 8.43 |
| 50-Day Moving Average | 9.40 |
| 20-Day Moving Average | 8.42 |
| 10-Day Moving Average | 8.34 |
| Average True Range | 0.64 |
| RSI (14) | 46.24 |
| ADX | 22.3 |
| +DI | 25.75 |
| -DI | 18.76 |
| Chandelier Exit (Long, 3 ATRs) | 7.89 |
| Chandelier Exit (Short, 3 ATRs) | 9.55 |
| Upper Bollinger Bands | 9.00 |
| Lower Bollinger Band | 7.84 |
| Percent B (%b) | 0.57 |
| BandWidth | 13.80 |
| MACD Line | -0.23 |
| MACD Signal Line | -0.32 |
| MACD Histogram | 0.091 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 10.65 | ||||
| Resistance 3 (R3) | 10.78 | 10.21 | 10.29 | ||
| Resistance 2 (R2) | 10.21 | 9.66 | 10.14 | 10.17 | |
| Resistance 1 (R1) | 9.35 | 9.32 | 9.07 | 9.22 | 10.05 |
| Pivot Point | 8.78 | 8.78 | 8.63 | 8.71 | 8.78 |
| Support 1 (S1) | 7.92 | 8.23 | 7.64 | 7.79 | 6.95 |
| Support 2 (S2) | 7.35 | 7.89 | 7.28 | 6.83 | |
| Support 3 (S3) | 6.49 | 7.35 | 6.71 | ||
| Support 4 (S4) | 6.36 |
